AngelEye Health Acquires EDNA Platform

Harnessing Sensors to Identify Risk in Infants with the Acquisition of the EDNA Portfolio

NASHVILLE, Tenn.--(BUSINESS WIRE)--AngelEye Health, the leading technology provider for neonatal and pediatric family engagement services, today announced the acquisition of Enlighten Mobility’s Early Detection Neuromotor Assessments (EDNA) portfolio, dedicated to identifying risk factors in newborns utilizing movement analysis, sensors, clinical experts, and artificial intelligence. This strategic acquisition strengthens AngelEye’s ability to harness sensors at the bedside to help care teams assess, identify, and support early intervention pathways in neonates.

With nearly 250 hospital partners and technology at 7,000+ bedsides, the integration of EDNA’s platform into AngelEye has the unique ability to significantly impact NICU care. “The acquisition of the EDNA portfolio is a pivotal moment for AngelEye,” said Christopher Rand, Chief Executive Officer of AngelEye Health. “By combining our industry-leading footprint with EDNA’s portfolio, we gain the ability to extend our reach beyond engagement and into the realm of supporting clinical care. This strategic transaction enables us to use our established relationships and infrastructure in the NICU to provide clinicians a greater capability to identify at-risk patients, and support their care journey in the NICU and beyond.”

Identifying risks, such as neuromotor, positioning, or sepsis, for example, in neonates, is challenging, which often leads to prolonged hospital stays and long-term complications. Through EDNA’s sensor-based platform, clinicians have more information to understand the neonates’ risks and can better support the baby and their family earlier in the infant’s life, leading to better outcomes.

“Early detection is critical for improving long-term outcomes for neonates and high-risk infants,” said Kathi Randall, NeuroNICU consultant. “Today, without early, validated, and accessible assessments for newborns, families and clinicians wait for clinical symptoms or significant delays to be identified, which can take weeks or months. AngelEye’s acquisition of the EDNA portfolio is a game-changer, providing clinicians with essential tools to identify and stratify high-risk babies earlier.”

EDNA’s algorithms and clinical service model have been developed in collaboration with leading scientists and hospitals, including Nationwide Children’s Hospital. Ongoing research is underway for the continued validation and discovery of additional sensor-based algorithms and services for newborns.

"At Nationwide Children's Hospital, our mission is to fuel scientific discovery for better patient care and advance the field of pediatrics through collaboration and innovation," said Matthew McFarland, Vice President of Commercialization and Industry Relations at Nationwide Children’s Hospital. "AngelEye's acquisition of the EDNA technology aligns with this mission, holding immense potential for making early detection assessments more widely accessible, ultimately improving care for children everywhere. We're thrilled to expand our strategic research collaboration with AngelEye Health on the EDNA portfolio."

This acquisition serves as a springboard for AngelEye’s continued innovation in neonatal care to reach beyond engagement at the bedside to support clinical care. To learn more, visit our website.

This press release contains information about a medical device product that has not yet received clearance from the U.S. Food and Drug Administration (FDA). The product is currently undergoing the necessary regulatory review process, and its safety and efficacy have not yet been established. Any statements regarding the product's potential benefits are based on preliminary data and are subject to change upon further evaluation and FDA approval.

About AngelEye

AngelEye Health is advancing NICU care by equipping care teams with tools that optimize workflow while empowering families through a comprehensive suite of technologies. We go beyond camera engagement solutions by providing a robust platform that integrates families into the care team more effectively. Our trusted solutions enable a powerful ecosystem that fosters a collaborative family-centered approach, focusing on the patient's well-being throughout the NICU journey. This holistic methodology, driven by cutting-edge technology, has a proven track record of improving family experiences, care delivery workflows, and patient outcomes.

Our live-stream cameras, feeding management system, and new discharge planning software support care teams and families from admission to discharge, delivering tangible benefits for hospital staff and patients. Since 2013, AngelEye has partnered with hundreds of hospitals across the US, Canada, EU, and Australia and boasts a retention rate of over 98% since our founding in 2013. We are committed to continuous innovation, shaping the NICU of the future where technology empowers families, optimizes care, and leads to the best possible outcomes for neonates.